Schedule IV Controlled Substance – Secure handling required
FIDOQUEL™ - CA1
(phenobarbital tablets)
Confidently Manage Canine Idiopathic Epilepsy
Trusted control, thoughtfully developed for dogs.
FIDOQUEL (phenobarbital tablets) is indicated for the control of seizures associated with idiopathic epilepsy in dogs 6 months of age and older.
FDA Conditionally Approved
Finally, Phenobarbital Made Specifically for Dogs
FIDOQUEL is the first phenobarbital conditionally approved by the FDA for the control of seizures associated with idiopathic epilepsy in dogs. It offers a reliable therapeutic option based on extensive clinical evidence and a history of phenobarbital use.1
Proven effectiveness
Studies on phenobarbital demonstrate that 82% of dogs achieved >50% seizure reduction, including 31% that became seizure-free.1
Formulated with purpose
Bisected tablets in multiple strengths for flexible, individualized dosing.
Professional Recognition
Phenobarbital use is supported by eight peer-reviewed publications, including the ACVIM and IVETF consensus guidelines.1
Available in 15–100 mg strengths
Twice-daily dosing with food
Beef-flavored tablets coming soon
FIDOQUEL allows titration based on individual clinical response, giving you the flexibility to adjust therapy for seizure control and safety.
Practical Benefits for Your Practice
Eliminate Human Drug Workarounds
Stop explaining to clients why you're using human medications. FIDOQUEL is purpose-built for dogs with veterinary-specific manufacturing standards.
Improve Client Conversations
When clients ask, "Is this the best option?", you can confidently say yes; it's FDA conditionally approved specifically for dogs like theirs.
Expert Support When You Need It
Direct access to Genus Lifesciences' technical team for dosing questions, adverse event guidance, and clinical support.
For use in dogs only
Lead the Way in Canine Seizure Control
FIDOQUEL is available now for prescribing veterinarians.
Order todayIMPORTANT SAFETY INFORMATION
Contraindicated in dogs with a history of hypersensitivity to phenobarbital. Do not use in pregnant or lactating dogs due to risk of congenital malformations during fetal development and accumulation in the milk of lactating dogs. Safety in dogs that are intended for breeding, pregnant or lactating, or neonates, has not been established.
Not for use in cats. Not for use in humans. Due to risks of developmental effects, women who are pregnant or may become pregnant should handle and administer FIDOQUEL™-CA1 with caution. Keep out of reach of children.
In case of accidental ingestion, skin reaction, or eye exposure, contact a physician immediately. In case of accidental exposure, rinse exposed area thoroughly.
Carefully monitor therapeutic, biochemical, and hematology parameters and adverse events, especially when administering concomitant medications and during dose adjustments. Dogs with decreased liver function are at increased risk of phenobarbital toxicosis.
Drug Abuse, Addiction, and Diversion: Contains phenobarbital, a Schedule IV controlled substance with potential for abuse, misuse, addiction, and diversion.
See Prescribing Information for complete product details.
References:
1. FIDOQUEL [prescribing information]. Allentown, PA: Genus Lifesciences Inc.; 2025.
FIDOQUELTM and it’s associated logo are trademarks of Genus Lifesciences, Inc. (C) 2025 Genus Lifesciences, Inc. All rights reserved. FID-0801-0009